Low Dose Naltrexone (LDN): immune modulation and inflammation support

Low Dose Naltrexone (LDN) is a low-dose form of naltrexone, a medication that has been used for many years in much higher doses to treat opioid and alcohol dependence. At standard doses, naltrexone works by blocking opioid receptors in the brain.
‍
When used at very low doses, typically a fraction of the standard dose, naltrexone appears to have different effects. In this low-dose range, it is thought to temporarily block opioid receptors, leading to a rebound increase in the body’s own endorphins and modulation of immune and inflammatory pathways.

LDN is used off-label in selected cases where immune disregulation, chronic inflammation, or pain sensitivity may be contributing to symptoms. Its use is based on emerging clinical evidence and clinician experience rather than large-scale guideline recommendations, and response varies between individuals.

LDN is generally well tolerated when prescribed and monitored appropriately.

Side effects with low dose naltrexone (LDN) are usually mild, short-lived, and dose-dependent, but they can vary between individuals. The most commonly reported effects include vivid dreams, sleep disturbance, headaches, nausea, or transient fatigue, particularly in the first few weeks of treatment.
‍
These effects often occur as the nervous and immune systems adjust and usually settle with time or dose adjustment. Starting at a very low dose and increasing gradually can reduce the likelihood and severity of side effects. LDN does not cause dependency and is not immunosuppressive at low doses.
‍
As with any medication, individual medical history, concurrent medications, and sensitivity to treatment are considered before prescribing, and response is monitored over time.

Response varies; some notice changes within weeks, others take longer.

No. It is considered when standard approaches are insufficient or unsuitable.

LDN is used selectively when immune or inflammatory drivers are present.